Tau Inhibitors - Pipeline Insight, 2025

DelveInsight’s, “Tau Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Tau Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tau Inhibitors: Understanding

Tau Inhibitors: Overview

Tauopathy is a class of neurodegenerative conditions that are associated with pathological phosphorylated tau protein accumulation in the human brain. Tauopathy has been associated with several clinicopathological conditions, including chronic traumatic encephalopathy (CTE), traumatic brain injuries, post-traumatic stress disorder, and Alzheimer’s disease (AD).

In humans, tau is encoded by a single gene on chromosome 17q21 containing 16 exons. Alternative splicing of exons 2, 3 and 10 allows for six tau isoforms with 352–441 amino acids, differing from each other by the presence of zero, one or two inserts (0 N, 1 N and 2 N) in its amino-terminal part and three or four microtubule-binding domains (3R or 4R) in its carboxy-terminal part. Tau is subject to a host of post-translational modifications, including phosphorylation, acetylation, ubiquitination, SUMOylation, glycosylation, nitration, methylation, prolyl-isomerization, glycation and truncation. Tau is abundant in axons, where it binds to microtubules, although it is also found in the neuron’s soma and dendrites at lower levels. Under normal conditions, tau is mainly involved in microtubule assembly and stabilization and contributes to the regulation of intracellular trafficking.

Microtubule-associated protein tau is characterized by the fact that it is an intrinsically disordered protein due to its lack of a stable conformation and high flexibility. Intracellular inclusions of fibrillar forms of tau with a β-sheet structure accumulate in the brain of patients with Alzheimer's disease and other tauopathies. Accordingly, detachment of tau from microtubules and transition of tau from a disordered state to an abnormally aggregated state are essential events preceding the onset of tau-related diseases. Animal and pathological studies using human samples have demonstrated that tau oligomer formation contributes to neuronal loss. During the progression of tauopathies, tau seeds are released from cells and incorporated into other cells, leading to the propagation of pathological tau aggregation

Accumulating evidence suggests several potential approaches for blocking tau-mediated toxicity:

direct inhibition of pathological tau aggregation and

(2) inhibition of tau post-translational modifications that occur prior to pathological tau aggregation,

(3) inhibition of tau propagation and

(4) stabilization of microtubules.

In addition to traditional low-molecular-weight compounds, newer drug discovery approaches such as the development of medium-molecular-weight drugs (peptide- or oligonucleotide-based drugs) and high-molecular-weight drugs (antibody-based drugs) provide alternative pathways to preventing the formation of abnormal tau.

Tau-targeted drugs may be a promising disease-modifying therapy because previous studies focusing on the correlation of AD neuropathological changes (Aβ plaques and NFT) with cognitive impairment have shown that the severity of cognitive impairment correlated best with the burden of abnormal tau.

“Tau Inhibitors - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Tau Inhibitors pipeline landscape is provided which includes the disease overview and Tau Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Tau Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tau Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Tau Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Tau Inhibitors.

Tau Inhibitors Emerging Drugs Chapters

This segment of the Tau Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tau Inhibitors Emerging Drugs

• TRx0237: TauRx Therapeutics

TRx0237 (LMTX) is an oral tau aggregation inhibitor developed by TauRx Therapeutics for Alzheimer's disease. It aims to dissolve neurofibrillary tangles formed by hyperphosphorylated tau proteins, which contribute to neurodegeneration. In clinical trials, it has shown mixed results, with some studies indicating cognitive and functional benefits in certain subgroups. TauRx continues to investigate its potential, positioning TRx0237 as a promising but experimental treatment in Alzheimer’s therapy. Currently, the drug is been Registered for the treatment of Alzheimer's disease.

• Bepranemab: UCB Biopharma

Bepranemab is a monoclonal antibody (mAb) that specifically targets a mid-region epitope of human tau In pathological conditions, the mid-region of tau is thought to be essential for tau aggregation and is a key driver of neurodegeneration in Alzheimer’s disease. APOε4 is the primary genetic risk factor for sporadic Alzheimer’s disease. UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2025. Results provide first evidence of biological and clinical effect of a mid-domain tau-targeting disease-modifying therapy. In full study population primary endpoint was not met, however in key secondary endpoints bepranemab slowed cognitive decline and rate of tau accumulation. In pre-defined patient subgroups, consistent treatment benefit shown across multiple primary and secondary outcome measures, including cognition and function. UCB is evaluating next steps in the development program. The drug is currently in Phase II stage of its development for the treatment of Alzheimer’s Disease.

• VY-7523: Voyager Therapeutics

Voyager Therapeutics’ investigational tau-targeting agent, VY-7523 (formerly referred to as VY-TAU01), is advancing as an anti-tau antibody therapy, aimed at treating Alzheimer’s disease. This therapy specifically targets pathological tau protein, a hallmark of neurodegenerative disorders like Alzheimer's. The initial Phase 1a trial, launched in early 2025, is a single ascending dose (SAD) study in healthy volunteers, designed to assess the safety and pharmacokinetics of VY-7523. This trial marks an important step toward addressing the spread of tau protein within the brain, a key factor linked to cognitive decline in Alzheimer’s patient. The drug is currently in Phase I stage of its development for the treatment of Alzheimer’s Disease.

Further product details are provided in the report……..

Tau Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Tau Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Tau Inhibitors

There are approx. 20+ key companies which are developing the therapies for Tau Inhibitors. The companies which have their Tau Inhibitors drug candidates in the most advanced stage, i.e. Registration include, TauRx Therapeutics.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Tau Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tau Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tau Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tau Inhibitors drugs.

Tau Inhibitors Report Insights

• Tau Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tau Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tau Inhibitors drugs?
• How many Tau Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tau Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tau Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tau Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• TauRx Therapeutics
• Prothena
• UCB Biopharma
• Oligomerix
• Voyager Therapeutics
• Alterity Therapeutics

Key Products

• TRx0237
• BMS-986446 (PRX005)
• Bepranemab
• OLX07010
• VY-7523
• ATH 434